Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference

Rhea-AI Summary

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will present at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. Eastern Time. The presentation will feature CFO Bill Peters, VP Dan Dischner, and SVP Tony Marrs. Investors can access the live webcast on Amphastar's website, which will be available for 90 days after the event. Amphastar specializes in developing and selling generic and proprietary injectable and inhalation products, primarily for hospital and urgent care settings.

RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time.

This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

About Amphastar:

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at www.amphastar.com.

The Amphastar Pharmaceuticals’ logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene^®, Amphadase^® and Cortrosyn^®, are the property of Amphastar Pharmaceuticals, Inc.

Forward-Looking Statement:

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control.  Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov.  The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.

Contact:

Bill Peters
Chief Financial Officer
(909) 476-3416

FAQ

What is the date and time of Amphastar's presentation at the BMO Healthcare Conference?

Amphastar's presentation is scheduled for June 23, 2020, at 1:00 p.m. Eastern Time.

Who will be presenting for Amphastar at the BMO Conference?

Bill Peters, CFO; Dan Dischner, VP of Corporate Communications and HR; and Tony Marrs, SVP of Regulatory Affairs and Clinical Operations will present.

How can I access the webcast of Amphastar's conference presentation?

The webcast can be accessed live on Amphastar's website and will be available for 90 days post-event.

What type of products does Amphastar Pharmaceuticals develop?

Amphastar develops generic and proprietary injectable, inhalation, and intranasal products, focusing on hospital and urgent care settings.

What stock symbol is associated with Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals is traded under the stock symbol AMPH on NASDAQ.